eureKING, the first European SPAC in healthcare dedicated to biomanufacturing, announces its intention to combine with Skyepharma to build a new European bio-CDMO leader
eureKING has a clear and identified roadmap to bolster Skyepharma’s technology platform to consolidate the highly fragmented European market in biomanufacturing capacity, such as state-of-the-art facilities to manufacture cell and gene therapies in Europe.